Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | PNP | P00491 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20819522 | 0.87 | XDH (0.38) | KDM4EALDH1A1RAB9AXDHPNP | |
| SCHEMBL2574470 | 0.86 | KDM4E (0.37) | KDM4EALDH1A1RAB9ATDP1XDH | |
| SCHEMBL10047094 | 0.80 | XDH (0.40) | KDM4EALDH1A1XDHPNPLMNA | |
| SCHEMBL5062459 | 0.80 | XDH (0.46) | KDM4EALDH1A1XDHPNPHTT | |
| SCHEMBL669008 | 0.78 | XDH (0.61) | KDM4EALDH1A1RAB9AXDHPNP | |
| SCHEMBL21183279 | 0.78 | XDH (0.44) | KDM4EALDH1A1XDHPNPLMNA | |
| SCHEMBL26174316 | 0.78 | XDH (0.53) | KDM4EALDH1A1XDHPNPHTT | |
| SCHEMBL9479049 | 0.77 | XDH (0.40) | ALDH1A1XDHPNPGDA | |
| SCHEMBL1398291 | 0.75 | GDA (0.42) | KDM4EALDH1A1PNPLMNAGDA | |
| SCHEMBL2623143 | 0.75 | XDH (0.65) | KDM4EALDH1A1XDHLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614071-B2 | Preferential amplification of mRNA over DNA using chemically modified primers | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2013-12-24 | — | — | US | claimed |
| EP-2337865-A1 | IMPROVED ALLELE-SPECIFIC AMPLIFICATION | Roche Diagnostics GmbH (DE) | 2011-06-29 | — | — | EP | claimed |
| WO-2010046067-A9 | IMPROVED ALLELE-SPECIFIC AMPLIFICATION | ROCHE DIAGNOSTICS GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
| WO-2010046067-A1 | IMPROVED ALLELE-SPECIFIC AMPLIFICATION | ROCHE DIAGNOSTICS GMBH (DE) | 2010-04-29 | — | — | WO | claimed |
| EP-1117838-B1 | A METHOD FOR ANALYZING POLYNUCLEOTIDES | VARIAGENICS INC (US) | 2009-05-13 | — | — | EP | claimed |
| US-11505815-B2 | Compositions and methods related to non-templated enzymatic nucleic acid synthesis | NUCLERA NUCLEICS, LTD. (GB) | 2022-11-22 | — | — | US | disclosed |
| EP-3710461-A1 | NUCLEOTIDE DERIVATIVES CONTAINING AMINE MASKED MOIETIES AND THEIR USE IN A TEMPLATED AND NON-TEMPLATED ENZYMATIC NUCLEIC ACID SYNTHESIS | Nuclera Nucleics Ltd (GB) | 2020-09-23 | — | — | EP | disclosed |
| CN-111344296-A | Nucleotide derivatives containing amine-masked moieties and their use in templated and non-templated enzymatic nucleic acid synthesis | 核酸有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-20190144905-A1 | Novel Use | Nuclera Nucleics Ltd. (GB) | 2019-05-16 | — | — | US | disclosed |
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120156679-A1 | METHODS FOR MAKING TRANSCRIPTION PRODUCTS | EPICENTRE TECHNOLOGIES (US) | 2012-06-21 | — | — | US | disclosed |
| US-8137911-B2 | Using promoter sequences and RNA polymerase to generate nucleotide sequences corresponding to target gene sequences; gene expression inhibition and diagnostic probe generation | CELLSCRIPT, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-1201676-A2 | PNA-DNA-PNA chimeric macromolecules | ISIS PHARMACEUTICALS, INC. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6277603-B1 | PEPTIDE NUCLEIC ACID (PNA); THE DNA PORTION IS COMPOSED OF SUBUNITS OF AT LEAST ONE 2'-DEOXYNUCLEOTIDES; INCREASED NUCLEASE RESISTANCE; ACTIVATE RNASE H ENZYME, USE FOR IN VITRO MODIFICATION OF RNA | ISIS PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
| EP-0734391-A4 | PNA-DNA-PNA CHIMERIC MACROMOLECULES | ISIS PHARMACEUTICALS INC (US) | 1998-02-25 | — | — | EP | disclosed |
| US-5700922-A | INCREASED NUCLEASE RESISTANCE, INCREASED BINDING AFFINITY TO COMPLEMENTARY STRANDS; MEDICAL DIAGNOSIS, THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0734391-A1 | PNA-DNA-PNA CHIMERIC MACROMOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995014706-A1 | PNA-DNA-PNA CHIMERIC MACROMOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| US-4579849-A | HERPES VIRUS | MERCK & CO., INC. (US) | 1986-04-01 | — | — | US | disclosed |
| EP-0161955-A1 | N-alkylguanine acyclonucleosides as antiviral agents | MERCK & CO. INC. (US) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505815-B2 | Compositions and methods related to non-templated enzymatic nucleic acid synthesis | RNGTT, DUT, PNP | KDM4E 1072/4885ALDH1A1 966/4885RAB9A 3909/4885 |
| US-20190144905-A1 | Novel Use | DUT, RNGTT, MTAP | KDM4E 1047/4885ALDH1A1 689/4885RAB9A 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.